FOR IMMEDIATE RELEASE Expression…

                                  FOR IMMEDIATE RELEASE

Expression Pathology Obtains SBIR to Identify Protein Biomarkers of
Breast Cancer Metastasis
Gaithersburg, MD: May 15, 2008: Expression Pathology Inc. (EPI) has been awarded a $148,000
Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI)
to employ its proprietary tissue microproteomics technologies to identify protein biomarkers of
metastasis in primary breast cancer. EPI's Liquid Tissue® sample preparation and DirectorTM laser
microdissection will enable in-depth mass spectrometry based proteomic profiling of archived
formalin-fixed tissue with detailed patient histories.

Over 200,000 cases of early-stage breast cancer present for treatment decisions each year in the US.
Although gene-expression tests have been developed to help guide those decisions, a protein-based
approach has the potential to be more widely available and more informative. Proteins make up the
molecular pathways which control cell functions and are the actual targets of most drugs.

"This project is a natural evolution of our business to use our proprietary tissue proteomics research
tools to understand at the protein level the progression of metastasis in early-stage breast cancer,"
said David Krizman, Ph.D., EPI's Chief Scientific Officer. "Our aim is to develop valuable tissue
protein assays that can aid patient treatment decisions, and to identify new therapeutic targets and
companion diagnostics to those targets. We greatly appreciate the NCI's SBIR program in its
support of innovative initiatives by early-stage companies like EPI."

About Expression Pathology Inc.
EPI is developing proprietary cancer tests and research tools to study and measure proteins in
formalin-fixed paraffin-embedded (FFPE) tissue, the format of patient tissue routinely collected and
stored in medical treatment and research facilities. FFPE tissue constitutes a huge, untapped
resource for discovery, validation and measurement of valuable biomarkers of disease progression,
drug response and toxicity.

EPI's Liquid Tissue® sample preparation and DirectorTM laser microdissection technologies enable
mass spectrometry-based analysis and measurement of proteins in FFPE tissue. EPI offers these as
research products, contract services and collaborative research programs. For more information, see
www.expressionpathology.com.

For more information, contact:

Expression Pathology Inc.
Peter Tunon, Vice President Sales and Marketing
9290 Gaither Road
Gaithersburg, MD 20877
Phone: (301) 977-3654
E-mail: p.tunon@expressionpathology.com